Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).

J Clin Oncol · 2021 · PMC8078437 · PMID 33555926

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

There was a slight trend for greater numbers of newly detectable TCR clones observed on treatment in the experimental arm (PEG + FOLFOX) compared with the control arm (FOLFOX) at C2D13 and C4D13 (Appendix Fig A 6 A, online only).

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.